Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • gandalf886
    Member
    • Feb 2013
    • 11

    #1

    whole genome bisulfite sequencing in mouse: how many reads required

    Hi,

    I am going to do some WGBS in mouse, before I start, could you give an idea how many reads I need in order to have a good CpG coverage? or how many lanes of hiseq2000 per sample should I do?

    Thanks
  • nucacidhunter
    Jafar Jabbari
    • Jan 2013
    • 1250

    #2
    I would recommend looking at “NIH RoadMap Epigenomics Mapping Consortium” website: http://www.roadmapepigenomics.org/

    As a ball point figure they recommend minimum of two biological replicates/treatment with combined 30x coverage (15x/strand). Most of available kits will result in fairly short insert (100-150 bp) bisulphite converted libraries suitable for 2x50 cycle sequencing. Assuming a 3 Gb mouse genome and 180 M read/lane output, each treatment will need approximately 5 lanes of HiSeq sequencing to obtain minimum recommended coverage.Taking into account mapping efficiency of 60-70% will increase lane number by 1.5-2 totalling 6.5-7 lane/treatment. So, for control and one treatment minimum of 13 lanes sequencing is required.

    Comment

    • dpryan
      Devon Ryan
      • Jul 2011
      • 3478

      #3
      It depends on what you want to do with the data. I have a dataset where I used a single flow-cell with one sample per lane. That'd be about the minimum I could ever recommend. Your mapping efficiency should be upwards of 80% with mouse data, though you'll end up using a smaller portion of that if you QC things properly. I ended up with ~6x CpG coverage per-sample (in total >30x).

      Depending on what you're doing, you might consider targeted bisulfite sequencing. There's now a mouse kit to target promoters and such (note, this isn't RRBS), so that might be a nice alternative. The costs and analysis can both become a bit more appealing then.

      Comment

      • gandalf886
        Member
        • Feb 2013
        • 11

        #4
        thanks guys

        Originally posted by nucacidhunter View Post
        I would recommend looking at “NIH RoadMap Epigenomics Mapping Consortium” website: http://www.roadmapepigenomics.org/

        As a ball point figure they recommend minimum of two biological replicates/treatment with combined 30x coverage (15x/strand). Most of available kits will result in fairly short insert (100-150 bp) bisulphite converted libraries suitable for 2x50 cycle sequencing. Assuming a 3 Gb mouse genome and 180 M read/lane output, each treatment will need approximately 5 lanes of HiSeq sequencing to obtain minimum recommended coverage.Taking into account mapping efficiency of 60-70% will increase lane number by 1.5-2 totalling 6.5-7 lane/treatment. So, for control and one treatment minimum of 13 lanes sequencing is required.
        Originally posted by dpryan View Post
        It depends on what you want to do with the data. I have a dataset where I used a single flow-cell with one sample per lane. That'd be about the minimum I could ever recommend. Your mapping efficiency should be upwards of 80% with mouse data, though you'll end up using a smaller portion of that if you QC things properly. I ended up with ~6x CpG coverage per-sample (in total >30x).

        Depending on what you're doing, you might consider targeted bisulfite sequencing. There's now a mouse kit to target promoters and such (note, this isn't RRBS), so that might be a nice alternative. The costs and analysis can both become a bit more appealing then.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
          by SEQadmin2



          Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

          Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
          ...
          10-14-2026, 09:55 AM
        • SEQadmin2
          New Genomics Technologies Take Aim at Long-Standing Limits
          by SEQadmin2


          Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

          We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
          ...
          09-28-2026, 10:25 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 10-22-2026, 11:13 AM
        0 responses
        61 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-22-2026, 10:48 AM
        0 responses
        43 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-15-2026, 10:52 AM
        0 responses
        76 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-14-2026, 05:39 AM
        0 responses
        74 views
        0 reactions
        Last Post SEQadmin2  
        Working...